Abstract: Objective To explore the efficacy of bronchial arterial chemotherapy（BAI） in treatment of non-small cell lung cancer（NSCLC）and the correlations with changes of serum excision repair cross complementing 1（ERCC1），vascular endothelial growth factor（VEGF） and soluble E-cadherin（SE-CAD）levels in patients with NSCLC before and after intervention therapy. Methods Image data of 60 NSCLC patients in the preoperative and postoperative were collected and to evaluate the shorttime curative effects and the levels of serum ERCC1， VEGF and SE-CAD were detected by ELISA before and after treatment in 60 patients with NSCLC treated by BAI. Results After 2 cycles treatment of BAI，the size of patients tumor has been controlled in various degrees with an effective rate of 61.7％，and the effective rate of squamous cell carcinoma and adenocarcinoma was 78.4％ and 34.8％（P＜0.05）. The expressions of serum ERCC1 after one week and one month increased significantly compared with pre-treatment（P＜0.05）. The effective rate of patients who had low serum ERCC1 after treatment of BAI was 71.1％ and high serum ERCC1 was 45.5％ of patients. Serum level of VEGF and SE-CAD decreased significantly compared with pre-treatment（P＜0.05）. The main toxic reactions were myelosupression，gastrointestinal reaction and stethalgia，and hepatic and kidney function lesion was with low occurrence rate. Conclusion BAI is one of safe and effective methods towards locally advanced NSCLC. Levels of serum ERCC1，VEGF and SE-CAD may be used as indicators of efficacy and prognosis.